Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Predictive factors of the response to H. pylori eradication in low grade B-cell lymphoma MALT patients

The major negative predictive factor of the tumoral response to anti-H. pylori treatment in patients with primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue is the presence of peri-gastric lymph nodes on endoscopic ultrasonography, a new study finds.

News image

fiogf49gjkf04

It is known that primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) can regress with conservative treatment.

This may include treatments such as anti-Helicobacter pylori therapy or mono-chemotherapy.

In order to assess the effects of adjuvant therapy in responding patients, and to evaluate an alternative therapy in non-responding patients, predictive factors of the response to anti-H. pylori treatment have been analyzed.

From 1995 to 2000, M. Levy and colleagues at the Hôpital Henri Mondor, in Creteil, France, treated 48 patients with anti-H. pylori therapy.

All 48 patients in the study group were previously H. pylori-infected, and had localized primary gastric low-grade B-cell lymphoma MALT.

Endoscopic and endoscopic ultrasonography features and histological grading of large cells' proportion were analyzed.

Non-responders to anti-H. pylori therapy:
58% achieved lymphoma remission with chlorambucil
American Journal of Gastroenterology

At two months and six months respectively, the efficacy of the H. pylori eradication therapy, and tumoral response, were also assessed.

From 1996, patients in remission at 6 months were randomized to receive either chlorambucil p.o. for 6 months or no treatment.

Patients who did not respond to H. pylori eradication received chlorambucil p.o. for 1 year.

Among the 48 treated patients, 33 (69%) were in complete (n = 28) or in partial (n = 5) remission, and 15 (31%) were in treatment failure at 6 months.

H. pylori was eradicated in 47 patients.

The response was not correlated with the endoscopic features or with the histological grade.

In contrast, it was related to ultrasonographic features: remission was achieved in 76% of patients when no peri-gastric lymph node was detected versus only 33% when endoscopic ultrasonography showed presence of lymph nodes.

All responding patients remained in remission (median 34 months) whatever the treatment they received (no treatment or chlorambucil).

Remission could be achieved with chlorambucil in 58% of the non-responding patients to anti-H. pylori treatment.

Writing in the American Journal of Gastroenterology, the authors say the major negative predictive factor of the tumoral response to anti-H. pylori treatment in these patients was the presence of peri-gastric lymph nodes on endoscopic ultrasonography.

In responding patients remission remained stable, suggesting that adjuvant chemotherapy was not useful.

Concluding, the authors write, "In patients who failed to respond to H. pylori eradication, mono-chemotherapy with chlorambucil proved to be efficient, but new therapeutic modalities should be evaluated to improve the control of the tumoral process."

Am J Gastroenterol 2002; 97(2): 292-7
13 March 2002

Go to top of page Email this page Email this page to a colleague

 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Sexual functioning in Hep C
 02 November 2017 
Rural residence and risk of IBD
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 20 October 2017 
Hospital readmissions reduction program
 19 October 2017 
Surgical anastomosis at 1-year colorectal cancer surveillance
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us